Answer
Tecartus (brexucabtagene autoleucel) is contraindicated in patients with hypersensitivity to its active substance or any excipient listed in section 6.1; contraindications to the lymphodepleting chemotherapy must also be considered.
Sources for this answer
- TecartusGilead Sciences Ltd · emc · SmPC §4.3 Contraindications · Version 18Document updated
Sources checked